)
Olympus (7733) investor relations material
Olympus Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 revenue was ¥269.2B, up 9% YoY reported and 1% in constant currency; adjusted operating margin was 17.8%, up 2.8pp reported and 0.2pp in constant currency, excluding the tariff refund.
FY2027 H1 revenue was ¥509.6B and operating profit ¥85.0B; first-half execution supported raised full-year guidance floors.
GIS led growth, while SIS Urology and Respiratory returned to double-digit growth; FDA-related product restrictions and quality remediation remained operating priorities.
Financial highlights
Q2 adjusted operating profit was ¥48.0B excluding the tariff refund, up 29% reported and 2% in constant currency; adjusted EPS was ¥32, up 38%.
H1 adjusted operating profit was ¥95.8B and profit attributable to owners was ¥52.1B; excluding the refund, adjusted operating profit was ¥78.7B and profit attributable to owners was ¥39.4B.
Q2 adjusted free cash flow was ¥14.4B, down ¥6.9B YoY; H1 operating cash flow was ¥62.3B and adjusted free cash flow was ¥23.6B.
Outlook and guidance
FY2027 revenue guidance is ¥1,064.5B–¥1,076.0B; operating profit guidance is ¥155.0B–¥167.5B and adjusted operating profit guidance is ¥186.5B–¥199.0B, including the tariff refund.
Excluding the tariff refund, adjusted operating profit guidance is ¥167.0B–¥179.5B and adjusted EPS guidance is ¥111–¥119; guidance floors were raised, and the year-end dividend outlook is ¥30 per share.
Management expects delayed North American GI capital deals to close in H2, citing a strong order book and positive underlying demand.
H2 catalysts include earlier-than-expected product returns from ship-holds and OPM-related SG&A benefits; management expects performance near the guidance midpoint.
China is expected to improve gradually in H2; FY2028 planning incorporates expected GI-ET pricing pressure from national VBP based on current information.
- FY2025 targets recovery after FY2024 earnings weakened under quality and impairment costs.7733
Q4 2024 - Strong revenue and profit growth, margin expansion, and BioProtect acquisition highlight the quarter.7733
Q1 2027 - AI-driven innovation and a division-led model underpin 3–5% annual growth and margin gains.7733
Status update - Innovation, AI, and operational efficiency drive robust growth in endoscopy-enabled care.7733
44th Annual J.P. Morgan Healthcare Conference - Global MedTech innovator advancing AI-driven endoscopy and sustainable healthcare solutions.7733
Company presentation - FY2027 guidance targets revenue growth, margin expansion, and continued capital returns.7733
Q4 2026 - Q3 revenue rose 4% YoY, but profit guidance was cut on ship-holds, tariffs, and higher costs.7733
Q3 2026 - Revenue and profit declined, but innovation and restructuring offer upside potential.7733
Q2 2026 - Revenue and profit fell sharply, with guidance cut due to tariffs and regulatory headwinds.7733
Q1 2026
Next Olympus earnings date
Next Olympus earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)